AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16546105
Drug: Conjunctival autografting
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjunctival autografting combined with one minute application of MMC, 0.2 mg/ml (Group 4)
Trial: 10660096
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 800 mg/day for 12 weeks
Trial: 380253
Drug: Paracetamol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (0.5 g x 4 for 3 days)
Trial: 380253
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (0.5 g x 4 for 3 days)
Trial: 367795
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Trial: 30404139
Drug: Random Forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random Forest model using a combination of three NDVI characteristics, three phenological characteristics, and two curve parameters as predictors for sunflower yield estimation
Trial: 22238353
Drug: Octreotide-LAR treatment
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide-LAR treatment for 48 months
Trial: 22238353
Drug: Inactive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive group after treatment
Trial: 22238353
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with homeostasis model of assessment‐insulin resistance
Trial: 22238353
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with growth hormone (GH)
Trial: 18094424
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g daily for 3 days)
Trial: 15951310
Drug: 4% dimeticone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% dimeticone lotion (applied for eight hours or overnight)
Trial: 10449124
Drug: Aldose reductase
RxNorm normalized name: Aldose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldose reductase inhibitor (ARI) zenarestat
Trial: 8714853
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream applied 60 min prior to local anesthesia
Trial: 8714853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EMLA cream)
Trial: 2220573
Drug: No ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ECG (n = 6 concurrent control patients)
Trial: 393076
Drug: Alcohol 1.2
RxNorm normalized name: dichlorobenzyl alcohol 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 1.2 g/kg
Trial: 393076
Drug: Diazepam 2
RxNorm normalized name: diazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 2 mg
Trial: 29727535
Drug: Pancreatic kininogenase
RxNorm normalized name: kininogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic kininogenase (120 u, tid) and sildenafil (25 mg, qd at bedtime)
Trial: 29727535
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg, qd at bedtime)
Trial: 21087222
Drug: Individualized nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized nutritional treatment from a dietitian in the hospital and three home visits after discharge
Trial: 21087222
Drug: Individualized nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized nutritional treatment
Trial: 9697784
Drug: General endotracheal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General endotracheal anesthesia with postoperative intravenous morphine patient-controlled analgesia
Trial: 7875666
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cefotaxime (2 g every 6 hours)
Trial: 7875666
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cefotaxime (2 g every 12 hours)
Trial: 2087437
Drug: Saline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.2 ml)
Trial: 35195
Drug: Clobazam 15
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 15 mg daily
Trial: 35195
Drug: Clobazam 30
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 30 mg daily
Trial: 35195
Drug: Diazepam 15
RxNorm normalized name: diazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 15 mg daily
Trial: 25575616
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal delivery system (MTS)
Trial: 11967499
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg
Trial: 15172084
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + medroxyprogesterone acetate (CEE/MPA) 5 mg
Trial: 11800516
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor-I treatment
Trial: 9591509
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of estradiol and progesterone
Trial: 7882660
Drug: Continuing education
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing education intervention 'Periodontics in General Practice' including a 1-day seminar, bi-monthly newsletters, individualized 3-monthly comparative feedback, and technical assistance.
Trial: 3255811
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (liquid nitrogen + wart paint)
Trial: 3255811
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid nitrogen applied weekly
Trial: 3255811
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of wart paint (lactic acid one part, salicylic acid one part, collodion four parts)
Trial: 27979383
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 3 weeks
Trial: 23666379
Drug: Focused Shockwave
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused Shockwave Therapy (FSWT)
Trial: 23666379
Drug: Radial Shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Shockwave Therapy (RSWT)
Trial: 23536950
Drug: Succinate-containing dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinate-containing dialysis solution (SCDS)
Trial: 23536950
Drug: Standard bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bicarbonate dialysis solution
Trial: 19453400
Drug: Inactivated, aluminium‐adjuvanted,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, aluminium‐adjuvanted, whole‐virion prototype pandemic influenza A (H5N1) vaccine (PanFlu)
Trial: 17211365
Drug: Dicumarol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicumarol therapy suspended and replaced by heparin-calcium in group D (control group)
Trial: 12950426
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg twice daily for 8 days
Trial: 12950426
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 8 days
Trial: 3533755
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil ester (1.5 g) with probenecid (1.0 g)
Trial: 3533755
Drug: Amoxycillin (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (3.0 g) plus clavulanic acid (0.25 g) with probenecid (1.0 g)
Trial: 17319482
Drug: Single-dose extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose extended-release epidural morphine (EREM) 10, 20, or 30 mg
Trial: 12714115
Drug: Aspirin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (low dose of 100mg daily or less)
Trial: 12714115
Drug: NSAIDs without
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs without aspirin
Trial: 12714115
Drug: Aspirin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (for individuals aged 75 years and over)
Trial: 12714115
Drug: Aspirin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (for individuals younger than 75 years)
Trial: 1539812
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl administration
Trial: 1539812
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl administration
Trial: 1539812
Drug: Both epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both epidural and intravenous fentanyl
Trial: 30396739
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation preoperatively
Trial: 26853645
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment with compression stockings and anticoagulants)
Trial: 23446197
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (PP; 234 mg day 1 and 156 mg day 8)
Trial: 23446197
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting injection (RLAI; 25 mg, days 8 and 22)
Trial: 22836068
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus colesevelam (3.75 g/day)
Trial: 6371696
Drug: Antenatal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroids (steroids)
Trial: 28805455
Drug: Telephone-based peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based peer support intervention (weekly calls for six weeks)
Trial: 27087149
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine candidate
Trial: 19926634
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg/kg given at skin incision and 3 hours later
Trial: 16145639
Drug: 0.125 %
RxNorm normalized name: kinetin 0.125 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 % bupivacaine plus 1 microg x ml (‐1) fentanyl
Trial: 16145639
Drug: 0.125 %
RxNorm normalized name: kinetin 0.125 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 % bupivacaine plus 0.75 microg x ml (‐1) clonidine
Trial: 12116326
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment
Trial: 12116326
Drug: Drill treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drill treatment
Trial: 2286697
Drug: Titrated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated dose of midazolam to produce light or heavy sedation
Trial: 2286697
Drug: Midazolam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (all treatment levels)
Trial: 31336184
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase support with hCG (1500 IU, two injections at three days interval)
Trial: 24178807
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone acetonide (IVTA) injection
Trial: 21862138
Drug: Bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 300 mg daily
Trial: 15292314
Drug: pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (30 mg/d)
Trial: 17482941
Drug: Verapamil 10
RxNorm normalized name: verapamil 100 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 10 mg/20 mL (Group 3)
Trial: 17482941
Drug: Verapamil 10
RxNorm normalized name: verapamil 100 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 10 mg/4 mL (Group 1)
Trial: 17482941
Drug: Verapamil 10
RxNorm normalized name: verapamil 100 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 10 mg/10 mL (Group 2)
Trial: 14693983
Drug: Inhaled fast‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fast‐acting human insulin via AERx iDMS
Trial: 14693983
Drug: Subcutaneous fast‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fast‐acting human insulin
Trial: 9795350
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone twice daily
Trial: 7986457
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive medication with no dietary intervention
Trial: 7986457
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive medication with sodium restriction
Trial: 7986457
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive medication with weight reduction for the obese
Trial: 7986457
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (return to antihypertensive medication)
Trial: 2590608
Drug: Intravenous oxpentifylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxpentifylline (200 mg in 10 ml saline)
Trial: 19101099
Drug: Motivation Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivation Enhancement Therapy (MET)
Trial: 19657294
Drug: Antioxidants (AOX)
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (AOX) supplementation (272 mg of alpha‐tocopherol, 400 mg of vitamin C, 30 mg of beta‐carotene, 2 mg of lutein, 400 mcg of selenium, 30 mg of zinc, and 600 mg of magnesium)
Trial: 15286093
Drug: Hydroxyzine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 30 mg (positive control)
Trial: 8340309
Drug: Fenfluramine (gradually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (gradually increased to 1.5 mg/kg/day)
Trial: 21078810
Drug: Prescription omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3 (8 g/d for the first 7 days, then 4 g/d through week 24)
Trial: 21078810
Drug: Prescription omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3
Trial: 8908223
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction at 133 mg · min‐1
Trial: 6126399
Drug: Oxatomide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (60 mg daily)
Trial: 6126399
Drug: Mequitazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mequitazine (10 mg daily)
Trial: 28357404
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) combined with pharmacological therapy
Trial: 24274317
Drug: Proposed herbal
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed herbal moisturising cream containing Arctium lappa L. seed extract
Trial: 15983823
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (200 ml) with atenolol (50 mg)
Trial: 15983823
Drug: Water (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (200 ml) with atenolol (50 mg)
Trial: 2400198
Drug: lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine 4 mg b.i.d.
Trial: 2400198
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg b.i.d.
Trial: 2400198
Drug: diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem 120 mg b.i.d.
Trial: 367025
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose calcium heparin
Trial: 367025
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose sodium heparin
Trial: 31916704
Drug: NRL-1 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL-1 (intranasal diazepam) 5 mg
Trial: 31916704
Drug: NRL-1 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL-1 (intranasal diazepam) 10 mg
Trial: 31916704
Drug: NRL-1 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL-1 (intranasal diazepam) 20 mg
Trial: 31916704
Drug: NRL-1 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL-1 (intranasal diazepam) 2 x 10 mg
Trial: 31916704
Drug: NRL-1 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL-1 (intranasal diazepam)
Trial: 31034106
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and cognitive behavioural therapy treatment
Trial: 28697043
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (OE) 2 mg/day
Trial: 28697043
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (OE) 2 mg/day + medroxyprogesterone acetate (MPA) 5 mg/day
Trial: 28697043
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 1 mg/day
Trial: 3292711
Drug: Postmastectomy radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmastectomy radiation added to chemotherapy
Trial: 30580488
Drug: 10-mL syringe
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-mL syringe
Trial: 23798329
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for patients aged < 50 years
Trial: 23798329
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for patients aged ≥ 50 years
Trial: 23798329
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for patients aged 50 to 54 years
Trial: 23798329
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for patients aged 55 to 59 years
Trial: 23798329
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for patients aged 60 to 64 years
Trial: 10932443
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment program for dual disorders (12 months duration)
Trial: 1436364
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment without dural closure
Trial: 6373685
Drug: Misonidazole (radiosensitizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (radiosensitizing drug)
Trial: 25643432
Drug: Low-dose intracoronary
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intracoronary UFH (1,000 IU intracoronary UFH)
Trial: 25643432
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (70-100 IU/kg intravenous UFH)
Trial: 11558045
Drug: 0.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 Gy (placebo dose)